A011801: The COMPASSHER2 Residual Disease Trial A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone in preventing breast cancer from returning? We are doing this study because we want to find out if this approach is better or worse than the usual approach for breast cancer.
Principal Investigator
Massey Cancer Center
Vachhani, Hetal (sub investigator/enrolling investigator is RHS)
Contact
Riverside Cancer Clinical Team
757-534-6890
[email protected]
Locations
All Peninsula Cancer Institute and Cancer Specialists of Tidewater sites
Status
Recruiting
Category
Oncology
Study #